SUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm

News provided by

May 02, 2017, 18:38 ET

NEW YORK, May 2, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Sunesis Pharmaceuticals Inc. ("Sunesis" or the "Company") (NASDAQ:SNSS).

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to appropriately disclose the suitability of the Company's treatment for elapsed/refractory acute myeloid leukemia ("AML"), vosaroxin, to receive approval in Europe.

Specifically, on May 2, 2017, Sunesis announced that the Company will withdraw its European Marketing Authorization Application for vosaroxin, following recent interactions with the European Medicine Agency's Committee for Medicinal Products for Human Use. The Company announced that it had learned that the committee was likely to formally adopt a negative opinion in its evaluation of the product, leading to its withdrawal.

On this news, Sunesis's share price fell from $3.66 per share on May 1, 2017 to a closing price of $2.96 on May 2, 2017—a $0.70 or a 19% drop.

If you invested in Sunesis stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/SNSS. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP